PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20145173-5	2010	We here examined the therapeutic efficacy of the combination of PD184352 with TZT-1027 or vinorelbine in nude mice harboring HT-29 or HT1080 tumor xenografts, in which the ERK pathway is activated as a result of mutations of BRAF and NRAS, respectively.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	64-72	mitogen-activated protein kinase 1	Mus musculus	172-175	
27913296-7	2017	PD184352 treatment reduced MEK/ERK phosphorylation and REDD1 protein expression, independent of insulin.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	0-8	mitogen-activated protein kinase 1	Mus musculus	31-34	
17907188-1	2007	OBJECTIVE: To evaluate the role of the MEK/ERK MAP kinase pathway in murine collagen-induced arthritis (CIA) using the selective MEK inhibitor PD184352.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	143-151	mitogen-activated protein kinase 1	Mus musculus	43-46	
19729613-4	2009	Here we determined the effect of simvastatin and the ERK inhibitor, CI1040, on AngII-stimulated AAA formation.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	68-74	mitogen-activated protein kinase 1	Mus musculus	53-56	
19492026-8	2009	PD184352 successfully decreased p-ERK level and inhibited renal cyst enlargement.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	0-8	mitogen-activated protein kinase 1	Mus musculus	34-37	
17880056-3	2007	This study afforded several compounds which were either equipotent or more potent than the clinical candidate CI-1040 (1) in an isolated enzyme assay, as well as murine colon carcinoma (C26) cells, as measured by suppression of phosphorylated ERK substrate.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	110-117	mitogen-activated protein kinase 1	Mus musculus	243-246	
16641154-7	2006	Administration of an oral MAP/ERK kinase inhibitor, PD184352, 400 mg/kg per d, to 10-wk-old pcy mice daily for the first week and then every third day for 6 additional weeks significantly decreased BP, kidney weight, serum creatinine level, and water intake and significantly increased urine osmolality.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	52-60	mitogen-activated protein kinase 1	Mus musculus	30-33	
16641154-8	2006	The cystic index and expression of phosphorylated ERK and ERK were significantly lower in PD184352-treated pcy mice.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	90-98	mitogen-activated protein kinase 1	Mus musculus	50-53	
16641154-8	2006	The cystic index and expression of phosphorylated ERK and ERK were significantly lower in PD184352-treated pcy mice.	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide	90-98	mitogen-activated protein kinase 1	Mus musculus	58-61